Tag: CereVasc
EShunt system receives US FDA Breakthrough Device designation for hydrocephalus treatment
Cerevasc has announced it has received Breakthrough Device designation from the US Food and Drug Administration (FDA) for its eShunt system, which is intended...
Cerevasc appoints two new medical device leaders to board of directors
Cerevasc has announced two new appointments to the company’s board of directors. Shlomi Nachman, former company group chairman of Cardiovascular and Specialty Solutions and...
Cerevasc secures US$70 million financing following US FDA approval of STRIDE...
Cerevasc announced recently that it has successfully completed the initial closing of a US$70 million Series B financing, which was jointly led by Bain Capital Life...
Cerevasc highlights eShunt study presentations from ABC WIN Seminar
Cerevasc has announced that data from clinical studies in the USA and Argentina examining the use of its eShunt system to treat communicating hydrocephalus were presented at...
Cerevasc announces multiple data presentations from CNS 2023
Cerevasc has announced that data from clinical studies examining the use of its eShunt system to treat elderly patients with normal-pressure hydrocephalus, and patients with...
Cerevasc announces US FDA-approved expansion of normal-pressure hydrocephalus study
Cerevasc has announced that the US Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) supplement to permit the expansion of...
Cerevasc announces presentation of initial eShunt data at ESMINT 2023
Cerevasc has today announced that findings from a clinical study examining the use of its eShunt system to treat communicating hydrocephalus were recently presented...
Cerevasc to present data on minimally invasive CNS delivery system at...
Cerevasc has announced that data on its minimally invasive central nervous system (CNS) delivery system will be presented for the first time at the...
Cerevasc appoints Adel Malek as its new chief medical officer
Cerevasc has named neurosurgeon Adel Malek as its new chief medical officer. This appointment will allow the company to further accelerate the development and clinical...
Cerevasc co-founders honoured with Innovation Award at SVIN 2022
Two neurosurgeons from Tufts Medical Center in Boston, USA have been honoured with the 2022 Innovation Award at this year’s Society of Vascular and...
CereVasc announces first treatment in US trial evaluating eShunt for normal-pressure...
CereVasc today announced completion of the first eShunt procedure in the USA as part of a pilot study involving normal-pressure hydrocephalus (NPH) patients.
The study is being conducted...
CereVasc announces US FDA approval for second IDE study of eShunt...
CereVasc announced today that the US Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to initiate a pilot trial...
Pedro Lylyk
Pedro Lylyk’s work and achievements in the neurosurgical field have spanned several decades, and range from a momentous intracranial stent placement in 1996, to...
First patient treated in clinical trial of CereVasc’s eShunt system for...
CereVasc has announced treatment of the first patient in its clinical study of the eShunt system in patients with normal-pressure hydrocephalus (NPH).
Following approval from Argentina's...
CereVasc receives FDA nod to study eShunt system in normal-pressure hydrocephalus...
CereVasc has announced that the US Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate a pilot trial...
CereVasc announces publication of first-in-human case report with eShunt system
CereVasc has announced the publication of a case report detailing the first treatment in a study of its eShunt system—an investigational device intended to...
First patient treated in eShunt clinical trial
CereVasc has announced the treatment of the first patient in a study of its eShunt System, an investigational device intended to treat communicating hydrocephalus...
